Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications
Vasomune Therapeutics Inc., and AnGes Inc., are pleased to announce that they have entered into an agreement to expand the research indications for the Tie2 receptor agonist Pegevongitide (AV-001) currently under joint development.
Vasomune Therapeutics Announces Poster Presentation at the American Thoracic Society International Conference
Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2025 American Thoracic Society (ATS) International Conference taking place May 16-21, 2025, at the Moscone Center, San Francisco, CA.
Vasomune Therapeutics Announces Poster Presentation at the American Thoracic Society International Conference
Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, today announced that the Company will present a Late-Breaking scientific poster at the upcoming 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, at the Manchester Grand Hyatt, San Diego, CA.
